MedPath
HSA Approval

ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML

SIN15971P

ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML

ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML

July 3, 2020

QT INSTRUMENTS (S) PTE LTD

QT INSTRUMENTS (S) PTE LTD

Regulatory Information

QT INSTRUMENTS (S) PTE LTD

QT INSTRUMENTS (S) PTE LTD

Therapeutic

Prescription Only

Formulation Information

SOLUTION

**4.2 Posology and method of administration** EndolucinBeta is only to be used by specialists experienced with _in vitro_ radiolabelling. Posology The quantity of EndolucinBeta required for radiolabelling and the quantity of Lutetium (177Lu)-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use. Refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled. Paediatric population For more information concerning paediatric use of Lutetium (177Lu)-labelled medicinal products refer to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled. Method of administration EndolucinBeta is intended for _in vitro_ radiolabelling of medicinal products which are subsequently administered by the approved route. EndolucinBeta should not be administered directly to the patient. For instructions on preparation of the medicinal product before administration, see section 12 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.

OTHERS

Medical Information

**4.1 Therapeutic indications** EndolucinBeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride.

**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). For information on contraindications to particular Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with EndolucinBeta, refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.

V10X

其它治疗用放射性药物

Manufacturer Information

QT INSTRUMENTS (S) PTE LTD

ITM Medical Isotopes GmbH

Active Ingredients

Lutetium (177Lu) Chloride

40 GBq/ml

Lutetium Lu-177

Documents

Package Inserts

PM_GBA_ELB_SmPC_SG_09_proposed.pdf

Approved: February 24, 2021

Download
© Copyright 2025. All Rights Reserved by MedPath